RRM1 and lung carcinoma: Recent studies of Asian and Western patients have firmly established that lipoprotein receptor-related protein-1, ribonucleotide reductase M1 (RRM-1), EGFR, and excision repair cross-complementing gene 1 (ERCC-1) may be useful molecular markers to guide drug selection in patients with lung cancer [9–13].